Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Bruce Strober Headshot

Bruce

Strober

,

MD, PhD

Clinical Professor
Yale University and Central Connecticut Dermatology
Cromwell
,
Connecticut
,
United States
Councilor Since: January 1, 2006
IPC President
Request an Update
Dr. Bruce Strober earned both his medical and doctoral degrees from Columbia University in New York, New York. He completed his dermatology residency at the Department of Dermatology, New York University School of Medicine. He is board-certified by the American Board of Dermatology and a Fellow of the American Academy of Dermatology (AAD).

Dr. Strober’s research interests focus on established and emerging therapies for inflammatory skin diseases, particularly interventions for challenging conditions such as psoriasis, atopic dermatitis, and hidradenitis suppurativa. He also explores novel aspects of these diseases and contributes to understanding their pathophysiology. Dr. Strober has served as a principal or sub-investigator in numerous multicenter clinical studies.

He holds the position of Clinical Professor of Dermatology at Yale University School of Medicine. Previously, he was the Editor-in-Chief of the Journal of Psoriasis and Psoriatic Arthritis, a Section Editor for the British Journal of Dermatology (BJD) , and has acted as an ad hoc reviewer for prestigious journals, including the Journal of the American Academy of Dermatology (JAAD), Journal of the American Medical Association (JAMA) Dermatology, BJD, and The New England Journal of Medicine (NEJM) . He has authored over 250 book chapters and articles in peer-reviewed journals such as JAMA Dermatology, NEJM, JAAD, Journal of Investigative Dermatology (JID) , and JAMA, among others. Dr. Strober has presented research data to the United States Food and Drug Administration (FDA), notably at advisory committee meetings for secukinumab, an innovative IL-17 inhibitor for the treatment of psoriasis. He currently serves as President on the Board of the International Psoriasis Council (IPC) and as Scientific Co-Director of the CorEvitas Psoriasis Registry.

His primary clinical practice focuses on treating complex inflammatory skin conditions, including psoriasis, atopic dermatitis, and hidradenitis suppurativa.

Before co-founding Central Connecticut Dermatology, Dr. Strober was Professor and Chair of the Department of Dermatology at the University of Connecticut School of Medicine in Farmington, Connecticut, United States.
Last Updated:
02/19/2026

Areas of Interest

Psoriasis Clinical Trials

IPC Committees / Groups

Board President, Executive Committee, Finance Committee, Governance Committee

Languages Spoken

English
Recent publications

Featured

Video

Bridging Psoriasis and Metabolic Comorbidities Toward Comprehensive Patient Management.

IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC's…

Watch Video

Blog

IPC Symposium at the 2026 Society for Investigative Dermatology (SID) Annual Meeting: Disease Interception, Treatment…

Read summaries from the IPC symposium at the 2026 Society for Investigative Dermatology (SID) Annual Meeting covering…

Read More

PDF

A Report from the 2026 American Academy of Dermatology (AAD) Annual Meeting.

What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis…

View Report

Blog

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic…

What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis…

Read More

Page

When Topicals Fail: The New IPC Consensus Every Clinician Should Know.

This podcast reviews the International Psoriasis Council (IPC) 2025 guidance on reclassifying psoriasis severity and…

View Report

Understanding IPC's Psoriasis Severity Reclassification - Available in 8 Languages.

Explore the IPC psoriasis severity reclassification and understand new criteria for identifying patients who may…

View Report

Blog

2025 IPC Think Tank Congress Report: Psoriasis, Metabolic Health, and GLP-1 Therapies.

The 2025 IPC Think Tank Congress Report highlights psoriasis as a systemic immunometabolic disease, linking obesity,…

Read More

PDF

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council…

The International Psoriasis Council (IPC) and the National Psoriasis Foundation (NPC) have released a joint position…

View Report

Video

Overview of Differential Diagnosis.

IPC President Dr. Bruce Strober outlines the wide differential diagnosis of scaly red skin conditions beyond…

Watch Video

Video

Establishing Consensus on Defining Failure of Topical Therapy in Psoriasis.

In this Take Ten with IPC video, IPC President Dr. Bruce Strober discusses IPC’s latest publication, which…

Watch Video

PDF

Establishing Consensus on Defining Failure of Topical Therapy in Psoriasis: Recommendations from the International…

Early and effective treatment in psoriasis mitigates cumulative chronic disease burden and may prevent psoriatic…

View Report

Blog

Focus on Psoriasis: Highlights from the 2025 ESDR Annual Meeting.

The 2025 ESDR Congress in Antwerp brought together over 1,000 dermatology researchers. This report summarizes the…

Read More

Blog

Focus on Psoriasis: Highlights from the 2025 EADV Congress.

At the 2025 EADV Annual Meeting in Paris, experts shared new insights into psoriasis diagnosis, symptoms, and…

Read More

PDF

A Report from the 34th Annual European Academy of Dermatology and Venereology (EADV) Congress.

Key takeaways from the 2025 EADV Congress in Paris, including the IPC Symposium on psoriasis, Free Communication…

View Report

Blog

Advancing Biosimilars and Optimizing Psoriasis Treatment: Highlights from the 2025 ICD Symposium.

Experts from across five continents discuss regional biosimilar uptake and practical strategies for optimizing…

Read More

Blog

Focus on Psoriasis: Highlights from the 2025 Society for Investigative Dermatology (SID) Annual Meeting.

IPC’s 2025 SID Congress Report highlights the most impactful psoriasis sessions, covering novel cell-biology…

Read More

Blog

Highlights from the 2025 American Academy of Dermatology (AAD) Annual Meeting: Psoriasis Comorbidities, New Treatments,…

The 2025 AAD Annual Meeting featured important updates on psoriasis therapies, comorbidities, and late-breaking…

Read More

Blog

Announcing IPC’s New Leadership for 2025.

Welcome the newest leadership to the IPC Board of Directors! Meet incoming IPC President Bruce Strober, Vice…

Read More

Blog

Focus on Psoriasis: A Report from the Psoriasis: From Gene to Clinic 10th International Congress.

The Psoriasis: From Gene to Clinic Congress Report highlights breakthroughs in genetics, clinical care, and treatment…

Read More

Event

IPC Psoriasis Masterclass for North America.

IPC MASTERCLASS | CHICAGO, ILLINOIS, UNITED STATES Program chairs: Melinda Gooderham, Canada and Bruce Strober,…

September 14, 2024
Learn More or Register

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026